Up Close with Ciltacabtagene Autoleucel
Last Updated: September 24, 2026
Review ciltacabtagene autoleucel indications, dosing, administration, monitoring, and key safety considerations.
Related Resources:
Perspectives
OncolyticsToday: The Bispecific Antibody Revolution
Author: KELLY BRUNK
Last Updated: 04/01/2024
Find Similar Resources:
CAR-T
CAR-T
CAR-T
CAR-T
Outpatient CAR-T Toxicity and Rapid-Escalation Playbook
Last Updated: 09/15/2026
Outpatient CAR-T Program Readiness Assessment and Implementation Roadmap
Last Updated: 09/15/2026
Outpatient CAR-T Patient and Caregiver Eligibility, Education, and Monitoring Toolkit
Last Updated: 09/14/2026
Community Cancer Center Working with CAR-T Centers
Last Updated: 09/14/2026
Immunotherapy
Immunotherapy
Immunotherapy
Immunotherapy
Overview of BTCEs: Comparison of Bispecific T-Cell Engagers (BTCEs)
Last Updated: 09/09/2026
Up Close with Linvoseltamab
Last Updated: 06/29/2026
Example SOPs and Documents: Transitioning Patients on Bispecific T-Cell Engagers Between Care Settings
Last Updated: 07/01/2025
Example SOPs and Documents: Bispecific T-cell Engager Billing Procedure
Last Updated: 07/01/2025
PQI Podcast
Toolkit
PQI
PQI
S11 E11: The Power of Connection: Building Stronger Teams and Finding Purpose
Last Updated: 11/06/2026
VA Community Care Referral and Authorization Checklist
Last Updated: 11/05/2026
PQI: Retifanlimab-dlwr in Combination with CARBOplatin + PACLItaxel for the First-Line Treatment of Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal
Last Updated: 10/21/2026
PQI: Ruxolitinib Extended Release for the Management of Myelofibrosis, Polycythemia Vera, and Graft-Versus-Host Disease
Last Updated: 10/21/2026